Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C
Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98104, USA.
J Clin Oncol. 1995 Oct;13(10):2547-55. doi: 10.1200/JCO.1995.13.10.2547.
To analyze factors that affect the collection of peripheral-blood stem cells (PBSC) before transplant and the tempo of engraftment after transplant.
A consecutive series of 243 patients with breast cancer (n = 87), malignant lymphoma (n = 90), multiple myeloma (n = 32), or other malignancies (n = 34) had PBSC collected following stimulation with colony-stimulating factors (CSFs) or after chemotherapy followed by CSF. Infusion of PBSC was performed following myeloablative chemotherapy with chemotherapy with or without total-body irradiation (TBI). Postinfusion CSFs were administered to 72 patients. An analysis of factors that influence CD34+ cell yield was performed by linear regression. Cox regression analysis was used to determine factors that affect the kinetics of granulocyte and platelet recovery following infusion of PBSC.
Mobilization with chemotherapy followed by CSF, a diagnosis of breast cancer, absence of marrow disease, no prior history of radiation therapy, and fewer cycles of conventional-dose chemotherapy were associated with a higher average daily yield of CD34+ cells. In the multivariate analysis, the CD34 content of infused cells and the use of a posttransplant CSF influenced neutrophil recovery after infusion of PBSC. CD34 content was also important for predicting platelet recovery. The use of postinfusion CSF was associated with a significant delay in platelet recovery in patients who received less than 5.0 x 10(6) CD34+ cells/kg, but there was no discernable effect in patients who received greater than 5.0 x 10(6) CD34+ cells/kg.
Disease status and prior treatment influence the ability to mobilize PBSC. CD34 cell dose is an important predictor of engraftment kinetics after PBSC transplant, regardless of disease or mobilization technique. The use of postinfusion CSF improves neutrophil recovery, but at low CD34 doses can delay platelet recovery.
分析影响移植前外周血干细胞(PBSC)采集及移植后植入进程的因素。
连续纳入243例乳腺癌患者(n = 87)、恶性淋巴瘤患者(n = 90)、多发性骨髓瘤患者(n = 32)或其他恶性肿瘤患者(n = 34),在集落刺激因子(CSF)刺激后或化疗后给予CSF采集PBSC。在进行有或无全身照射(TBI)的清髓性化疗后输注PBSC。72例患者在输注后给予CSF。通过线性回归分析影响CD34+细胞产量的因素。采用Cox回归分析确定影响输注PBSC后粒细胞和血小板恢复动力学的因素。
化疗后给予CSF进行动员、乳腺癌诊断、无骨髓疾病、无既往放疗史以及常规剂量化疗周期较少与较高的CD34+细胞平均日产量相关。多因素分析中,输注细胞的CD34含量及移植后CSF的使用影响输注PBSC后的中性粒细胞恢复。CD34含量对预测血小板恢复也很重要。对于接受少于5.0×10(6) CD34+细胞/kg的患者,输注后CSF的使用与血小板恢复显著延迟相关,但对于接受大于5.0×10(6) CD34+细胞/kg的患者没有明显影响。
疾病状态和既往治疗影响PBSC的动员能力。无论疾病或动员技术如何,CD34细胞剂量是PBSC移植后植入动力学的重要预测指标。输注后CSF的使用可改善中性粒细胞恢复,但在低CD34剂量时会延迟血小板恢复。